TRZ
Tirz is a dual GLP-1 and GIP receptor agonist studied in glucose-regulation and metabolic research.
We have not published an audit on TRZ. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
• Demonstrated up to 22.5% body weight reduction in clinical trials • Once-weekly subcutaneous injection for improved adherence • Significant HbA1c reduction (up to 2.58% in SURPASS trials) Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) [Source: Peptide Protocol Wiki]
Tirzepatide is a once-weekly injection that activates two appetite and blood-sugar hormones at the same time, GIP and GLP-1, helping the body release insulin after meals, slow digestion, and reduce appetite more effectively than drugs that only target GLP-1.
Reported side effects
The most common side effects are nausea, diarrhea, vomiting, and indigestion, which are usually worst when the dose is being increased and tend to improve once the dose stabilizes.
Who should avoid it
People with a personal or family history of medullary thyroid cancer or MEN 2, those who are pregnant, those with prior pancreatitis, severe gut motility disorders, or type 1 diabetes should not use tirzepatide, and those on oral contraceptives need backup birth control when starting or increasing the dose.
What gets monitored
No specific monitoring or bloodwork suggested. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for TRZ or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 5 mg once weekly · Low: 2.5 mg once weekly · High: 15 mg once weekly | once weeklyCycle length Planning note 4 weeks (Phase 1, 2. | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: 5 days. Tirzepatide is administered once weekly, starting at 5 mg. |
| 2.5 mg starting dose, escalating to 5-15 mg maintenance | Once weeklyOngoing (chronic therapy) | subcutaneous or oral | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
Common questions
What is the starting dose of tirzepatide?
The starting dose is 2.5 mg once weekly via subcutaneous injection for the first 4 weeks.
What is the highest dose of tirzepatide / Zepbound?
The maximum FDA-approved dose is 15 mg once weekly.
What is tirzepatide's half-life?
Tirzepatide's half-life is approximately 5 days.
How do you convert tirzepatide mg to insulin units?
Insulin syringes use U-100 markings, where 1 mL = 100 units.
How much weight can you lose on tirzepatide?
In SURMOUNT-1, the 15 mg arm averaged −22.5% body weight loss at 72 weeks.
How do you reconstitute tirzepatide?
For a 40 mg lyophilized vial, add 2.0 mL of bacteriostatic water for a 20 mg/mL solution.
Check 40 mg in 2 mL in the calculator →Is tirzepatide FDA-approved?
Yes, Mounjaro was FDA-approved in May 2022 for type 2 diabetes.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound contain the same active drug, tirzepatide, in the same titration ladder.
Sources
- 01Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (2022)
- 02Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine (2025)
- 03Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine (2021)
- 04Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet (2021)
- 05Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA (2022)
- 06Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine (2024)
The reference sections above are imported from our compound knowledge base, which classes the evidence for TRZ as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.